Zacks: Analysts Expect AnaptysBio Inc (NASDAQ:ANAB) Will Announce Earnings of -$1.14 Per Share

Wall Street analysts expect AnaptysBio Inc (NASDAQ:ANAB) to report earnings per share (EPS) of ($1.14) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for AnaptysBio’s earnings, with the lowest EPS estimate coming in at ($1.47) and the highest estimate coming in at ($0.77). AnaptysBio posted earnings per share of ($0.66) in the same quarter last year, which would indicate a negative year over year growth rate of 72.7%. The company is scheduled to report its next quarterly earnings results on Thursday, November 14th.

Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow AnaptysBio.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The business had revenue of $5.00 million for the quarter. The business’s revenue for the quarter was up 4900.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.57) earnings per share.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus set a $63.00 price objective on shares of AnaptysBio and gave the stock a “hold” rating in a report on Monday. SunTrust Banks cut their price target on shares of AnaptysBio from $125.00 to $93.00 and set a “buy” rating for the company in a report on Monday, June 24th. Credit Suisse Group cut their price target on shares of AnaptysBio from $79.00 to $75.00 and set a “neutral” rating for the company in a report on Friday, August 9th. HC Wainwright set a $126.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a report on Monday, June 24th. Finally, Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating in a report on Wednesday. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $111.50.

Shares of NASDAQ:ANAB traded down $0.99 during midday trading on Friday, reaching $50.47. 4,297 shares of the company’s stock were exchanged, compared to its average volume of 239,003. The business has a 50 day moving average price of $53.81. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -20.25 and a beta of 1.37. AnaptysBio has a 12 month low of $46.03 and a 12 month high of $110.00.

In other news, CEO Hamza Suria sold 22,428 shares of AnaptysBio stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the completion of the sale, the chief executive officer now owns 31,524 shares in the company, valued at approximately $2,325,210.24. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Marco Londei sold 10,060 shares of AnaptysBio stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $73.06, for a total transaction of $734,983.60. Following the sale, the insider now owns 32,437 shares of the company’s stock, valued at approximately $2,369,847.22. The disclosure for this sale can be found here. Company insiders own 14.00% of the company’s stock.

Large investors have recently modified their holdings of the company. Nuveen Asset Management LLC bought a new position in AnaptysBio in the second quarter valued at approximately $5,606,000. Price T Rowe Associates Inc. MD lifted its position in shares of AnaptysBio by 18.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 937,273 shares of the biotechnology company’s stock worth $52,881,000 after purchasing an additional 147,292 shares in the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of AnaptysBio by 4.3% in the second quarter. UBS Asset Management Americas Inc. now owns 102,034 shares of the biotechnology company’s stock worth $5,757,000 after purchasing an additional 4,164 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of AnaptysBio in the second quarter worth $205,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of AnaptysBio by 304.0% in the second quarter. Cubist Systematic Strategies LLC now owns 13,098 shares of the biotechnology company’s stock worth $739,000 after purchasing an additional 9,856 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Article: SEC Filing

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.